Valcare Medical is dedicated to providing innovative minimally-invasive technologies for the treatment of mitral and tricuspid regurgitation. Our product line includes solutions for the repair and replacement of the mitral valve as well as the repair of the tricuspid valve. Our breakthrough mitral valve treatment platform is based on a D-shaped ring which serves both as a docking station for Valcare’s unique replacement prosthesis, and as a highly-effective tool for mitral annulus repair.

Our mitral repair and replacement systems as well as our tricuspid repair solution establish Valcare as a leader in valve care, a responsibility we very much take to heart.


Steve Sandweg


Steve has over 25 years of medical device leadership experience. Focusing on the development of Cardiovascular and Structural Heart Technologies: EBR Systems, Inc. (CCO); Keystone Heart, Venus Medtech (GM); Direct Flow Medical®, (Director Market Dev); Medtronic CoreValve (District Sales Manager)



Mr. Omer Ostro has 10 years of executive-level financial management experience at both private and public companies in the finance and high-tech sectors. Prior to joining Valcare Medical, over the past few years Mr. Ostro has been providing outsourced financial advisory, control and CFO services, primarily in the high-tech and bio-med sectors, as well as financial expert opinions to courts and insurance companies.

Previously, he managed the valuation team of Emerging Market Structured Credit desk at Barclays Investment Bank in London and served as a Senior Associate at PwC Israel. Omer is a Certified Public Accountant and holds a B.Sc in Economics and Accounting (Magna Cum Laude) from Tel Aviv University and an M.Sc in Finance and Economics (with Merit) from the London School of Economics – LSE


VP R&D and Engineering

Mr. Nadav Yellin has years of experience in design, development and management of R&D Projects in the field of cardiovascular devices. He has been involved with Valcare since the inception of the company in 2012 and is leading product development.

Prior to joining Valcare, he served as team leader for Medtronic Ventor, designing and developing implants and delivery systems for percutaneous mitral valve treatments. Previously, Mr. Yellin served as a mechanical design engineer at Israeli Aircraft Industries. Nadav holds a B.Sc in Mechanical Engineering as well as a B.Sc in Biomedical Engineering from Ben Gurion University, Israel.



Dr. David Meerkin is an interventional cardiologist and a pioneer of interventions in structural and congenital heart disease. His experience covers most procedures in this field with emphasis on occlusion devices as well as the mitral valve, having developed a leading center for structural and congenital interventions in Jerusalem. Dr. Meerkin has been extensively involved in device development for nearly two decades consulting for many Israeli and international companies. A regular speaker at leading international conventions, Dr. Meerkin trained in Medicine in Melbourne, Australia, specialized in Internal Medicine and Cardiology at the Shaare Zedek Medical Center in Jerusalem and subsequently in Interventional Cardiology at the Montreal Heart Institute in Canada.


Director of Regulatory and Clinical Affairs

Ms. Anat Eitan brings to Valcare experience in regulatory and clinical affairs both in medical device and pharma industries. Prior to joining Valcare, Ms. Eitan worked at Refine Ltd. providing in-house regulatory services and clinical trial support to medical device companies in several medical fields. Her combined clinical and regulatory experience led to successful regulatory submissions.

Previously, Anat held clinical trial positions at EnzySurge Ltd., a medical device company, and at Averion International CRO. She moved to the clinical trial field following years of clinical experience as a clinical dietitian at Sheba Medical Center and at the Public Health Services in Israel